X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
transurethral alprostadil (84) 84
humans (72) 72
male (69) 69
erectile dysfunction (53) 53
urology & nephrology (47) 47
erectile dysfunction - drug therapy (43) 43
impotence (41) 41
men (40) 40
sildenafil citrate (36) 36
middle aged (29) 29
alprostadil - administration & dosage (28) 28
aged (25) 25
alprostadil (25) 25
erectile dysfunction - therapy (24) 24
vasodilator agents - administration & dosage (23) 23
double-blind (22) 22
erectile dysfunction - etiology (21) 21
purines (21) 21
sildenafil (21) 21
alprostadil - therapeutic use (20) 20
efficacy (20) 20
index medicus (19) 19
sulfones (19) 19
therapy (19) 19
phosphodiesterase inhibitors - therapeutic use (18) 18
piperazines - therapeutic use (18) 18
adult (17) 17
oral sildenafil (16) 16
quality-of-life (16) 16
medicine, general & internal (15) 15
vasodilator agents - therapeutic use (15) 15
safety (14) 14
sexual dysfunction (14) 14
penile erection (13) 13
pharmacology & pharmacy (13) 13
treatment outcome (13) 13
erectile dysfunction - diagnosis (12) 12
erectile dysfunction - physiopathology (12) 12
prostaglandin-e1 (12) 12
radical prostatectomy (12) 12
urethra (12) 12
care and treatment (11) 11
muse (10) 10
patient satisfaction (10) 10
penile erection - drug effects (10) 10
injection (9) 9
intracavernous alprostadil (9) 9
penis - blood supply (9) 9
prostatectomy - adverse effects (9) 9
alprostadil - adverse effects (8) 8
combination therapy (8) 8
drug therapy (8) 8
penile prosthesis (8) 8
piperazines - administration & dosage (8) 8
prostate cancer (8) 8
aged, 80 and over (7) 7
complications and side effects (7) 7
corpus cavernosum (7) 7
diagnosis (7) 7
injections (7) 7
intracavernous injection (7) 7
medicine & public health (7) 7
nitric-oxide (7) 7
papaverine (7) 7
prostatectomy (7) 7
quality of life (7) 7
risk factors (7) 7
drug therapy, combination (6) 6
erectile dysfunction - epidemiology (6) 6
health aspects (6) 6
injection therapy (6) 6
intracavernous injection therapy (6) 6
intraurethral alprostadil (6) 6
medicated urethral system (6) 6
penile rehabilitation (6) 6
risk-factors (6) 6
vasodilator agents - adverse effects (6) 6
administration, topical (5) 5
andrology (5) 5
depressive symptoms (5) 5
dysfunction (5) 5
failure (5) 5
female (5) 5
international index (5) 5
intracavernous alprostadil alfadex (5) 5
penile erection - physiology (5) 5
phentolamine (5) 5
phosphodiesterase inhibitors - administration & dosage (5) 5
prostaglandin e (5) 5
prostaglandin e-1 (5) 5
prostatic neoplasms - surgery (5) 5
radical retropubic prostatectomy (5) 5
research (5) 5
retropubic prostatectomy (5) 5
self-injection (5) 5
surgery (5) 5
vardenafil dihydrochloride (5) 5
vasoactive intestinal polypeptide (5) 5
alprostadil - pharmacology (4) 4
apomorphine sl (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of Sexual Medicine, ISSN 1743-6095, 01/2013, Volume 10, Issue 1, pp. 130 - 171
Erectile dysfunction (ED) is the most frequently treated male sexual dysfunction worldwide. ED is a chronic condition that exerts a negative impact on male... 
Erectile Dysfunction | Phosphodiesterase Inhibitors | Vacuum Device Therapy | Oral Drug Treatment | Combination Therapies | Transurethral Alprostadil Therapy | Intracavernous Self-Injection Therapy | Intracavernous Self‐Injection Therapy | INTRACAVERNOUS ALPROSTADIL ALFADEX | BENIGN PROSTATIC HYPERPLASIA | PHOSPHODIESTERASE TYPE-5 INHIBITOR | URINARY-TRACT SYMPTOMS | ONCE-A-DAY | LONG-TERM SAFETY | UROLOGY & NEPHROLOGY | QUALITY-OF-LIFE | PLACEBO-CONTROLLED TRIAL | VACUUM CONSTRICTION DEVICE | SELF-INJECTION THERAPY | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Middle Aged | Sulfones - adverse effects | Male | Alprostadil - therapeutic use | Erectile Dysfunction - therapy | Aged, 80 and over | Imidazoles - therapeutic use | Imidazoles - adverse effects | Risk Factors | Phosphodiesterase 5 Inhibitors - administration & dosage | Alprostadil - adverse effects | Yohimbine - adverse effects | Piperazines - therapeutic use | Sulfones - pharmacokinetics | Carbolines - administration & dosage | Piperazines - adverse effects | Sulfonamides - pharmacokinetics | Yohimbine - therapeutic use | Tadalafil | Vardenafil Dihydrochloride | Pyrimidines - pharmacokinetics | Hypogonadism - therapy | Triazines - adverse effects | Sulfonamides - administration & dosage | Sulfones - administration & dosage | Triazines - pharmacokinetics | Piperazines - administration & dosage | Sulfones - therapeutic use | Age Factors | Triazines - therapeutic use | Imidazoles - administration & dosage | Imidazoles - pharmacokinetics | Phosphodiesterase 5 Inhibitors - pharmacokinetics | Alprostadil - administration & dosage | Erectile Dysfunction - drug therapy | Penile Erection - drug effects | Adult | Phosphodiesterase 5 Inhibitors - therapeutic use | Piperazines - pharmacokinetics | Drug Therapy, Combination | Carbolines - therapeutic use | Carbolines - adverse effects | Pyrimidines - administration & dosage | Erectile Dysfunction - etiology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Triazines - administration & dosage | Hypogonadism - complications | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Carbolines - pharmacokinetics | Hypertension | Care and treatment | Conservatism | Online health care information services | Impotence | Prosthesis | Chronic diseases | Risk factors | Testosterone | Implants, Artificial | Prostaglandins E | Diabetes | Vasoactive intestinal peptides | Special education
Journal Article
Current Opinion in Urology, ISSN 0963-0643, 12/2015, Volume 26, Issue 2, pp. 123 - 128
Journal Article
ACTAS UROLOGICAS ESPANOLAS, ISSN 0210-4806, 12/2015, Volume 39, Issue 10, pp. 635 - 640
Introduction: Phosphodiesterase-5 inhibitors (PDE5i) are the first choice for treating erectile dysfunction (ED) but are not always effective. The aim of this... 
COMBINATION THERAPY | SILDENAFIL CITRATE | Erectile dysfunction | RADICAL PROSTATECTOMY | Alprostadil | Intraurethral | FAILURE | SATISFACTION | VARDENAFIL | MEN | UROLOGY & NEPHROLOGY | HYPERTENSION | TRANSURETHRAL ALPROSTADIL
Journal Article
Urology, ISSN 0090-4295, 2006, Volume 68, Issue 2, pp. 386 - 391
To assess the safety and efficacy of topical alprostadil cream for erectile dysfunction (ED). Patients with an ED score of 25 or less on the erectile function... 
UROLOGY & NEPHROLOGY | EFFICACY | SAFETY | MEN | TRANSURETHRAL ALPROSTADIL | Double-Blind Method | Erectile Dysfunction - drug therapy | Humans | Middle Aged | Male | Dosage Forms | Administration, Topical | Alprostadil - administration & dosage | Care and treatment | Impotence | Alprostadil | Analysis
Journal Article
Journal Article
British Journal of Urology, ISSN 0007-1331, 06/1998, Volume 81, Issue 6, pp. 889 - 894
Objective  To examine the safety and efficacy of transurethral pharmacotherapy for erectile dysfunction, involving the use of a novel therapeutic system to... 
Transurethral application | alprostadil | erectile dysfunction | Alprostadil | Erectile dysfunction | transurethral application | IMPOTENCE | INJECTION | UROLOGY & NEPHROLOGY | PROSTAGLANDIN-E1
Journal Article